NewsSource: EClinCloud Official Website Archive

EClinCloud and R&G PharmaStudies Deepen Strategic Partnership to Advance Intelligent Clinical Trial Management

3 min readEClinCloud Editorial Team
Archived article cover: EClinCloud and R&G PharmaStudies deepen strategic partnership to advance intelligent clinical trial management

EClinCloud and R&G PharmaStudies jointly announced that they will deepen their strategic partnership. Building on a solid foundation of collaboration in CTMS (clinical trial management system) and eTMF (electronic trial master file), the two parties will continue working together to advance the further application of solutions including EDC (electronic data capture), eCOA (electronic clinical outcome assessment), and scale copyright management.

This collaboration aims to further strengthen operational synergy and data interoperability across systems, while introducing AI technology to comprehensively enable and enhance the digitalization and intelligence of clinical trial management.

 

一临云与诺思格战略合作标识  

 

Platform-Based Collaboration to Enhance Digital Capabilities in Clinical Trials

 

The strategic partnership between EClinCloud and R&G PharmaStudies centers on "deep platform integration." Leveraging EClinCloud's mature, integrated intelligent cloud platform, the two parties deeply integrate R&G PharmaStudies' end-to-end clinical operations workflows with intelligent tools, covering full-lifecycle management from study design and data capture (EDC) to clinical endpoint assessment (eCOA). Enabled by AI technology, both parties achieve data interoperability and efficient operational collaboration across clinical trial management systems.

 

AI-Driven, Leading the Intelligent Transformation of Clinical Trial Management

 

The deep application of AI technology provides strong momentum for the collaboration between EClinCloud and R&G PharmaStudies. EClinCloud has comprehensively integrated AI technology across its product lines, significantly enhancing the level of intelligence in clinical trial management. For example:

CTMS: AI-enabled intelligent workflow optimization and automated quality control ensure efficient project timeline progression while providing real-time monitoring of data quality. 

eTMF: Intelligent document management and automated retrieval capabilities significantly improve document filing and review efficiency, increasing document organization efficiency by 20%.

In addition, both parties will further advance the intelligent application of digital solutions such as EDC and eCOA, optimizing operational efficiency and data quality across the entire clinical trial workflow, enhancing standardization and compliance in trial management, helping accelerate and improve the efficiency of new drug R&D, and ultimately benefiting more patients.

 

R&G PharmaStudies Co-Founder and Chief Operating Officer Dr. Teng Leyan said:

"Through AI-driven data integration and process automation, EClinCloud's integrated intelligent cloud platform will play an important role in improving clinical trial operational efficiency and optimizing project management for R&G PharmaStudies. This deep collaboration enables us to efficiently manage more complex projects and advance new drug development."

 

EClinCloud Founder & CEO Dr. Qin Long emphasized:

"We are committed to providing the industry with efficient and precise digital solutions for clinical research. As an innovative pioneer in the clinical trial field, R&G PharmaStudies is closely aligned with our vision of advancing the industry's digital transformation. Together, both parties will continue to explore more efficient and intelligent clinical trial management models to help sponsors optimize their R&D processes."  

 

About EClinCloud

EClinCloud is a leading AI technology company in the clinical research industry, leveraging AI to build an integrated intelligent clinical cloud platform and endpoint assessment technologies. It provides global pharmaceutical companies and research institutions with technology products such as eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, along with scale management, linguistic validation, rater training, and data quality analysis services to build efficient and precise digital solutions. Relying on AI predictive models and an intelligent data platform, EClinCloud dynamically evaluates and helps improve the success rate of drug clinical trials, helping shorten drug and medical device R&D cycles to benefit patients.

 

About R&G PharmaStudies

R&G PharmaStudies (stock code: 301333 SZ) is a well-known China-based, globally oriented CRO that provides global pharmaceutical companies with comprehensive, end-to-end clinical R&D CRO services—improving drug R&D success rates, reducing risks, saving costs, and shortening timelines—and has earned broad recognition across the industry. Its more than ten subsidiaries cover regulatory affairs, clinical pharmacology, medical affairs and pharmacovigilance, data management and biostatistics, clinical operations, site management, bioanalysis, and related services. To date, R&G PharmaStudies has served nearly 1,000 pharmaceutical companies, helping numerous pharmaceutical and medical device products adopt innovative designs and scientific methodologies, facilitate efficient communication with the CDE and FDA, and accelerate market launch.

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.